CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI Ticagrelor with or without Aspirin in High-Risk Patients after PCI Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI

Clinical Trial2020 Nov 12;S0140-6736(20)32236-4.

JOURNAL:Lancet. Article Link

Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial

J Silvain, B Lattuca, ALPHEUS investigators et al. Keywords: ticagrelor vs. clopidogrel; periprocedural myocardial necrosis; stable coronary artery disease; aspirin and clopidogrel; intravenous cangrelor;

Full Text PDF